T cells are an important part of our immune memory and offer a wealth of valuable information about the way our bodies perceive and respond to pathogens. Learn how this information is being harnessed and applied in the fight against COVID-19.Read More
The 21st century has seen a revolution in how we approach research. With the advent of new technologies like automation and machine/deep learning, biology is becoming a less inferential and more data-driven discipline. With scientific research delayed worldwide due to the COVID-19 pandemic, is it time to re-examine the future role of automation in biological research?
In a study recently published in Cell Systems, a new ultra-high-throughput proteomics method was used to identify 27 blood biomarkers that distinguished COVID-19 patients with mild or severe responses. We spoke to Dr Markus Ralser to learn more about the study and how the method could potentially be used in the clinic to diagnose COVID-19 severity.Read More
To learn about the benefits of accelerating turnaround times for genomic testing and the importance of partnering with pharma companies to develop companion diagnostics, Technology Networks spoke with Luca Quagliata, PhD, BCMAS, global director of medical affairs for Thermo Fisher Scientific.Read More
Here, Dr Pretorius examines the use of saliva, rather than blood, in rapid diagnostic tests for malaria and how this clinically informative biofluid could help to improve healthcare in the world’s poorest regions.Read More
As the world continues to battle through the pandemic, developing innovative strategies to expand the availability of extraction, and any other testing components that are facing supply issues, will be an ongoing requirement.Read More
Technology Networks recently spoke to Quanterix's Kevin Hrusovsky to hear more about how the company's technology is being applied in the pursuit of a biomarker for Alzheimer's disease, a progressive neurodegenerative condition for which diagnosis often occurs after the onset of symptoms.Read More
SomaLogic recently announced an agreement with the biopharmaceutical company Amgen that aims to advance Amgen's drug discovery and development programs through comprehensive proteomic profiling. We spoke with Roy Smythe to discover what barriers have been holding proteome analysis back, and how the collaboration with Amgen aims to change the landscape of drug discovery.Read More